Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 08/05/13 -- Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in with George Mack of The Life Sciences Report, " (OTCQX: CYNAF) (TSX VENTURE: CTH) is a small Canadian company developing a sublingual formulation of a drug called apomorphine, which is a rescue medication for Parkinson's disease patients who experience something called 'off time,' a rigid or frozen state that occurs when their levodopa + carbidopa medication has worn off. This typically happens in the morning, because the Parkinson's patient takes his or her last dose of medication before bed, and it has worn off by the time they awaken. Apomorphine is a rapid rescue medication for that "off time" state. Cynapsus' sublingual film formulation of apomorphine is put under the tongue and dissolves in a very short period of time. Patients with dyskinesia can take it themselves. It just makes sense.
"I think it could be a $500M or more opportunity. Parkinson's is an enormous indication, and almost all Parkinson's patients experience this on/off phenomenon. This is a very clean, low-risk story, and I love the way Cynapsus has pulled this off, being the first to patent this delivery. If this were a U.S. stock, it would be four or five times the price it is now, but because it's in Canada, no one knows about it."
Continue reading this interview with Jason Napodano, ""
To Read Jason Napodano's comments on other companies, visit .
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide valuable insights, integrated with in-depth company information, summaries from the latest research, and news that will help you make smart investment decisions.
Streetwise Reports, LLC - The Life Sciences Report
Brandon Fung
Email:
Tel: 707-981-8107
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.08.2013 - 13:37 Uhr
Sprache: Deutsch
News-ID 284691
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report"
steht unter der journalistisch-redaktionellen Verantwortung von
Streetwise Reports LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
